イスラエル - ヘブライ語 - Ministry of Health

novartis israel ltd - valsartan - טבליות מצופות פילם - valsartan 160 mg - valsartan - valsartan - for treatment of hypertension. diovan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial diovan signicantly reduced hospitalisations for heart failure. there is no evidence that diovan provides added benefits when it is used with an adequate dose of an ace inhibitor. diovan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

イスラエル - ヘブライ語 - Ministry of Health

novartis israel ltd - valsartan - טבליות מצופות פילם - valsartan 40 mg - valsartan - valsartan - diovan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial diovan significantly reduced hospitalisations for heart failure. there is no evidence that diovan provides added benefits when it is used with an adequate dose of an ace inhibitor. diovan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

イスラエル - ヘブライ語 - Ministry of Health

unipharm ltd - valsartan 40 mg - film coated tablets - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalizations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

イスラエル - ヘブライ語 - Ministry of Health

unipharm ltd, israel - valsartan - טבליה - valsartan 160 mg - valsartan - valsartan - for treatment of hypertension. valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalizations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

イスラエル - ヘブライ語 - Ministry of Health

dexcel pharma technologies ltd - valsartan - טבליות מצופות פילם - valsartan 40 mg - valsartan - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalisations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

イスラエル - ヘブライ語 - Ministry of Health

dexcel pharma technologies ltd - valsartan - טבליות מצופות פילם - valsartan 80 mg - valsartan - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalisations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

イスラエル - ヘブライ語 - Ministry of Health

dexcel pharma technologies ltd - valsartan - טבליות מצופות פילם - valsartan 160 mg - valsartan - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalisations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

イスラエル - ヘブライ語 - Ministry of Health

medison pharma ltd - daptomycin 500 mg/vial - lyophilized powder for injection - daptomycin - cubicin (daptomycin for injection) is indicated for the treatment of complicated skin and skin structure infections caused by susceptible strains of the following gram-positive microorganisms: staphylococcus aureus (including methicillin-resistant strains) streptococcus pyogenes streptococcus agalactiae streptococcus dysgalactiae subsp. equisimilis and enterococcus faecalis (vancomycin-susceptible strains only). combination therapy may be clinically indicated if the documented or presumed pathogens include gram-negative or anaerobic organisms. daptomycin is not indicated for the treatment of pneumonia. appropriate specimens for microbiological examination should be obtained in order to isolate and identify the causative pathogens and to determine their susceptibility to daptomycin. empiric therapy may be initiated while awaiting test results. antimicrobial therapy should be adjusted as needed based upon test results. to reduce the development of drug-resistant bacteria and maintain the effectiveness of cubici

イスラエル - ヘブライ語 - Ministry of Health

gilead sciences israel ltd - amphotericin b - אבקה להכנת תרכיז לאינפוזיה - amphotericin b 50 mg/vial - amphotericin b - amphotericin b - antifungal antibiotic for the treatment of severe systemic and/or deep mycoses where toxicity precludes the use of conventional systemic amphotericin b in effective dosages. this drug should not be used to treat the common clinically inapparent forms of fungal disease which show only positive skin or serologic tests. ambisome is also indicated for the treatment of systemic fungal infections in immunocompromised patients (e.g. patients with aids or cancer). ambisome is also indicated for the primary therapy of visceral leishmaniasis in immunocompetent patients and immunocompromised patients (e.g. hiv positive). empirical treatment of presumed fungal infection in febrile neutropenic patients.

イスラエル - ヘブライ語 - Ministry of Health

merck sharp & dohme israel ltd - ribavirin - קפסולות - ribavirin 200 mg - ribavirin - ribavirin - rebetol is indicated for the treatment of chronic hepatitis c and must only be used as part of a combination regimen with peginterferon alfa-2b (adults) or interferon alfa-2b (adults). rebetol monotherapy must not be used. there is no safety or efficacy information on the use of rebetol with other forms of interferon (i.e., not alfa-2b).previously untreated (na?ve) patients rebetol is indicated in adult patients :• in combination with peginterferon alfa-2b or interferon alfa-2b , for the treatment of adult patients with chronic hepatitis c, not previously treated, without liver decompensation, with elevated alanine aminotransferase (alt), who are positive for serum hcv-rna . additionally, rebetol is indicated , in combination with peginterferon alfa-2b, for the treatment of adult patients with chronic hepatitis c ,not previously treated, without liver decompensation, with elevated alanine aminotransferase (alt), who are positive for serum hcv-rna including patients with clinically stable hiv co-infection. pre